EverydayHealthLogo
Dr. Arash Alizadeh, MD, PHD

Dr. Arash Alizadeh, MD, PHD

Stanford, CA

16 Years of Experience

Accepting patients

Affiliated with a Castle Connolly Top Hospital

    Who is Dr. Alizadeh, Medical Oncologist in Stanford, CA?

    Dr. Arash Alizadeh, MD, PHD is a Medical Oncologist, who primarily practices in Stanford, CA with 2 additional practice locations. He has been practicing for over 16 years and is board certified by the American Board of Internal Medicine. Dr. Alizadeh completed his residency at Stanford University School of Medicine - Stem Cell Institute Dr Weissman's Laboratory. Dr. Alizadeh is fluent in English and Persian, and is currently seeing new patients. Dr. Alizadeh’s practice accepts Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Alizadeh’s office at (650) 498-6000.

    Where did Dr. Alizadeh go to medical school and complete their residency?

    • Fellowship: Stanford University School of Medicine,Stanford, Ca, United States

    • Residency: Stanford University School of Medicine - Stem Cell Institute Dr Weissman's Laboratory

    Is Dr. Alizadeh board certified in Medical Oncologist?

    Yes, Dr. Arash Alizadeh, MD, PHD is board certified by the American Board of Internal Medicine since 2009

    What languages does Dr. Alizadeh speak?

    Dr. Alizadeh and their clinical team can communicate with patients in the following languages:

    • English

    • Persian

    What conditions does Dr. Alizadeh treat?

    As a Medical Oncologist, Dr. Alizadeh diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Alizadeh. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.

    Also known as:

    • Diffuse Large B-cell Lymphoma
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Follicular Lymphoma
    • Waldenstrom Macroglobulinemia
    • MALT Lymphoma
    • Small B-cell Lymphoma
    • B-cell Lymphoma
    • Lymphoma
    • Waldenstrm macroglobulinemia
    • DLBCL
    • Aggressive B-cell Lymphoma
    • Diffuse B-cell Lymphoma
    • Lymphatic Cancer
    • Lymphosarcoma
    • NHL
    • MCL
    • Mantle Cell Lymphoma Cancer
    • Follicular Lymphatic Cancer
    • Indolent Lymphoma
    • Follicular Non-Hodgkin Lymphoma
    • FL
    • Nodular Lymphoma
    • Lymphoplasmacytic Lymphoma', 'WM Lymphoma', 'Waldenstrom's Disease
    • Mucosa-associated lymphoid tissue lymphoma
    • Extranodal marginal zone lymphoma
    • B-cell lymphoma
    • Large B-cell Lymphoma
    • Small Lymphocytic Lymphoma
    • SLL
    • Follicular Lymphoma Cancer
    • B-cell Non-Hodgkin Lymphoma
    • B-NHL
    • B-cell Lymphosarcoma

    ICD-10 Codes:

    • C8330: Diffuse large B-cell lymphoma, unspecified site
    • C8580: Other specified types of non-Hodgkin lymphoma, unspecified site
    • C8310: Mantle cell lymphoma, unspecified site
    • C8200: Follicular lymphoma grade I, unspecified site
    • C8290: Follicular lymphoma, unspecified, unspecified site
    • C8338: Diffuse large B-cell lymphoma, lymph nodes of multiple sites
    • C880: Waldenstrom macroglobulinemia
    • C884: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
    • C8334: Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
    • C8300: Small cell B-cell lymphoma, unspecified site
    • C8298: Follicular lymphoma, unspecified, lymph nodes of multiple sites
    • C8318: Mantle cell lymphoma, lymph nodes of multiple sites
    • C8307: Small cell B-cell lymphoma, spleen
    • C8331: Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
    • C8510: Unspecified B-cell lymphoma, unspecified site
    • C8218: Follicular lymphoma grade II, lymph nodes of multiple sites
    • C8800: Waldenstrom macroglobulinemia not having achieved remission
    • C83398: Diffuse large B-cell lymphoma of other extranodal and solid organ sites

    Also known as:

    • Chronic Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia Treatment (PDQ®)
    • CLL
    • B-cell chronic lymphocytic leukemia
    • Lymphocytic leukemia

    ICD-10 Codes:

    • C9110: Chronic lymphocytic leukemia of B-cell type not having achieved remission

    Also known as:

    • Muscle Disorder
    • Myopathy
    • Muscle Disease
    • Muscle Weakness Condition

    ICD-10 Codes:

    • G7289: Other specified myopathies

    Which procedures does Dr. Alizadeh perform as a Medical Oncologist?

    As a Medical Oncologist, procedures performed by a Dr. Arash Alizadeh may include:

    For detailed information, please contact Dr. Alizadeh's office.

    Does Dr. Alizadeh accept my insurance?

    Dr. Alizadeh accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.

    What insurance plans does Dr. Alizadeh accept in Stanford, CA?

    Dr. Alizadeh in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.

    Top Insurances

    • Advantage

    • All Other Third Party

    • Blue Shield of California

    • CVS Health (formerly Aetna)

    • Hill Physicians Medical Group

    • Humana

    • Medicare

    • OptumRx

    • Santa Clara Family Health Plan

    • UnitedHealthcare

    View All Insurances

    Where is Dr. Alizadeh's office located?

    Dr. Arash Alizadeh's Primary Practice

    300 Pasteur Dr

    Stanford, CA 94305

    (650) 498-6000

    Get Directions

    Dr. Arash Alizadeh's Practice 2

    269 Campus Dr # Ccsr

    Stanford, CA 94305

    Get Directions

    Dr. Arash Alizadeh's Practice 3

    875 Blake Wilbur Dr

    Palo Alto, CA 94304

    Get Directions

    Recognitions

    Publications

    Association of a Leukemic Stem Cell Gene Expression Sigture With Clinical Outcomes

    JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION, 2010

    Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma

    NEW ENGLAND JOURL OF MEDICINE, 2009

    SOURCE: a unified genomic resource of functiol annotations, ontologies, and gene expression data

    NUCLEIC ACIDS RESEARCH, 2003

    Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    TURE, 2000

    The lymphochip: A specialized cD microarray for the genomic

    Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Po, 1999

    High PD-1 expression

    Blood, 2013

    Germil centre protein HGAL promotes lymphoid hyperplasia

    TURE COMMUNICATIONS, 2013

    Hierarchy in Somatic Mutations Arising During Genomic Evolution

    Green, M. R., Gentles, A. J., ir, R. V., Irish, J. M., Levy, R., Aliza

    Identification of Candidate Transcriptiol Biomarkers Associated with Chronic Graft-Versus

    Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S

    Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies

    Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Aliz

    Cell-free D as a Biomarker of Residual Disease Following Radiation Therapy for Non

    Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu,, 2012

    CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T

    AMERICAN JOURL OF PATHOLOGY, 2012

    The chemoattractant chemerin suppresses melanoma by recruiting tural killer cell antitumor defenses

    JOURL OF EXPERIMENTAL MEDICINE, 2012

    The chemoattractant chemerin as a tural tumor suppressive cytokine.

    Pachynski, R. K., Zabel, B., Tejeda, N., Monnier, J., Holzer, A. K., G

    The CD47-sigl regulatory protein alpha

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2012

    First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma

    JOURL OF CLINICAL MICROBIOLOGY, 2012

    Three differentiation states risk-stratify bladder cancer into distinct subtypes

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2012

    Treatment advances have not improved the early death rate in acute promyelocytic leukemia

    HAEMATOLOGICA-THE HEMATOLOGY JOURL, 2012

    Correction: Specific post

    Arthritis research & therapy, 2012

    Specific post-translatiol histone modifications of neutrophil extracellular traps as immunogens

    ARTHRITIS RESEARCH & THERAPY, 2012

    Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Prelimiry Results

    Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J.,, 2011

    A few good genes Simple, biologically motivated sigtures for cancer prognosis

    CELL CYCLE, 2011

    Utility of positron emission tomography scans in mantle cell lymphoma

    AMERICAN JOURL OF HEMATOLOGY, 2011

    Impact of TET2 mutations on mR expression

    HEMATOLOGICAL ONCOLOGY, 2011

    Prospective separation of normal and leukemic stem cells based on differential expression of TIM3

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2011

    Therapeutic Antibody Targeting of CD47 Elimites Human Acute Lymphoblastic Leukemia

    CANCER RESEARCH, 2011

    Calreticulin Is the Domint Pro-Phagocytic Sigl on Multiple Human Cancers

    SCIENCE TRANSLATIOL MEDICINE, 2010

    NF-kappa B Sigling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome

    Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, 2010

    Second-line mitoxantrone, etoposide

    AMERICAN JOURL OF HEMATOLOGY, 2010

    B-cell sigling networks reveal a negative prognostic human lymphoma cell subset that emerges during

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2010

    Gene Expression Sigture of Host Immune Response

    Alizadeh, A. A., Gentles, A. J., Plevritis, S. K., Levy, R., 2009

    A pluripotency sigture predicts histological transformation

    Blood

    Evaluation and magement of angioimmunoblastic T-cell lymphoma

    Clinical advances in hematology & oncology : H&O, 2008

    Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germil center

    LEUKEMIA & LYMPHOMA, 2008

    Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan

    JOURL OF CLINICAL MICROBIOLOGY, 2007

    Distinct IL-4-induced gene expression, proliferation

    BLOOD, 2005

    AID is expressed in germil center B-cell-like

    LEUKEMIA, 2004

    Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

    NEW ENGLAND JOURL OF MEDICINE, 2004

    Gene expression sigture of fibroblast serum response predicts human cancer progression

    PLoS biology, 2004

    T cell receptor-independent basal sigling via Erk and Abl kises suppresses RAG gene expression

    PLOS BIOLOGY, 2003

    T cell receptor-independent basal sigling via Erk and Abl kises suppresses RAG gene expression.

    PLoS biology, 2003

    Individuality and variation in gene expression patterns in human blood

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2003

    Molecular heterogeneity in acute rel allograft rejection identified by D microarray profiling

    N Engl J Med, 2003

    Software tools for high-throughput alysis

    AMERICAN JOURL OF PATHOLOGY, 2002

    Genomic expression programs and the integration of the CD28 costimulatory sigl in T cell activation

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2002

    Transformation of follicular lymphoma to diffuse large-cell lymphoma

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2002

    The t(14;18) defines a unique subset of diffuse large B

    BLOOD, 2002

    Stereotyped and specific gene expression programs in human inte immune responses to bacteria

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2002

    Relation of gene expression phenotype to immunoglobulin mutation genotype

    JOURL OF EXPERIMENTAL MEDICINE, 2001

    Towards a novel classification of human maligncies based on gene expression patterns

    JOURL OF PATHOLOGY, 2001

    Genomic alysis of rel allograft dysfunction using cD microarrays

    Sarwal, M., Chang, S., Barry, C., Chen, X., Alizadeh, A., Salvatierra,, 2001

    Ongoing immunoglobulin somatic mutation in germil center B cell-like but not in activated B cell

    PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 2000

    Exploring gene expression sigtures of host responses to infection

    Boldrick, J. C., Belcher, C. E., Alizadeh, A. A., Liu, C. L., Diehn, M, 2000

    Examining the living genome in health and disease with D microarrays

    JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION, 2000

    Genomic-scale gene expression profiling of normal and malignt immune cells

    CURRENT OPINION IN IMMUNOLOGY, 2000

    Gene expression in large B-cell lymphoma using cD microarray technology.

    Chan, W. C., Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H.,, 1999

    Genome-wide alysis of D copy-number changes using cD microarrays

    TURE GENETICS, 1999

    Probing lymphocyte biology by genomic-scale gene expression alysis

    JOURL OF CLINICAL IMMUNOLOGY, 1998

    Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes

    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010

    Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B

    Cell, 2010

    CD47 Is an Adverse Prognostic Factor

    CELL, 2009

    Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma

    NEW ENGLAND JOURNAL OF MEDICINE, 2009

    SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data

    NUCLEIC ACIDS RESEARCH, 2003

    Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    NATURE, 2000

    The lymphochip: A specialized cDNA microarray for the genomic

    Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., Po, 1999

    Identification of gene microarray expression profiles in patients with chronic graft-versus

    Clinical immunology, 2013

    Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma.

    Blood, 2013

    Rituximab use and survival after diffuse large B-cell or follicular lymphoma

    LEUKEMIA & LYMPHOMA, 2013

    Hierarchy in somatic mutations arising during genomic evolution

    Blood, 2013

    High PD-1 expression

    Blood, 2013

    Germinal centre protein HGAL promotes lymphoid hyperplasia

    NATURE COMMUNICATIONS, 2013

    Hierarchy in Somatic Mutations Arising During Genomic Evolution

    Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Levy, R., Ali

    Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell

    Newman, A. M., Gentles, A. J., Plevritis, S. K., Alizadeh, A. A.

    Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression

    Liu, C. L., Dai, B., Newman, A. M., Majeti, R., Alizadeh, A. A.

    Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus

    Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S

    Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies

    Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Aliz

    Self-antigen recognition by follicular lymphoma B-cell receptors

    BLOOD, 2012

    Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non

    Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu,, 2012

    Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma

    PLOS ONE, 2012

    CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T

    AMERICAN JOURNAL OF PATHOLOGY, 2012

    The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor

    JOURNAL OF EXPERIMENTAL MEDICINE, 2012

    A retrospective study evaluating the efficacy

    LEUKEMIA & LYMPHOMA, 2012

    The chemoattractant chemerin as a natural tumor suppressive cytokine.

    Pachynski, R. K., Zabel, B., Tejeda, N., Monnier, J., Holzer, A. K., G

    The CD47-signal regulatory protein alpha

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2012

    First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma

    JOURNAL OF CLINICAL MICROBIOLOGY, 2012

    Three differentiation states risk-stratify bladder cancer into distinct subtypes

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2012

    Treatment advances have not improved the early death rate in acute promyelocytic leukemia

    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012

    Correction: Specific post

    Arthritis research & therapy, 2012

    Specific post-translational histone modifications of neutrophil extracellular traps as immunogens

    ARTHRITIS RESEARCH & THERAPY, 2012

    Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results

    Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J.,, 2011

    A few good genes Simple, biologically motivated signatures for cancer prognosis

    CELL CYCLE, 2011

    A proteomic approach for the identification of novel lysine methyltransferase substrates

    EPIGENETICS & CHROMATIN, 2011

    Utility of positron emission tomography scans in mantle cell lymphoma

    AMERICAN JOURNAL OF HEMATOLOGY, 2011

    Impact of TET2 mutations on mRNA expression

    HEMATOLOGICAL ONCOLOGY, 2011

    Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia

    CANCER CELL, 2011

    Prediction of survival in diffuse large B

    BLOOD, 2011

    Prospective separation of normal and leukemic stem cells based on differential expression of TIM3

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2011

    CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

    BLOOD, 2011

    Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

    CANCER RESEARCH, 2011

    Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers

    SCIENCE TRANSLATIONAL MEDICINE, 2010

    NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome

    Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, 2010

    Prediction of Survival In Diffuse Large B

    Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, , 2010

    Noninvasive Prediction of Graft-Verus

    Kohrt, H. E., Li, L., Alizadeh, A. A., Goldstein, M. J., Strober, S., , 2010

    Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma

    Layn, K., Alizadeh, A. A., Kattah, N., Levy, S., Levy, R., 2010

    Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14

    Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D, 2010

    Second-line mitoxantrone, etoposide

    AMERICAN JOURNAL OF HEMATOLOGY, 2010

    B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2010

    Expression profiles of adult T-cell leukemia-lymphoma

    LEUKEMIA & LYMPHOMA, 2010

    Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)

    LEUKEMIA RESEARCH, 2010

    Noninvasive Prediction of Graft-Versus

    Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., N, 2010

    Is Time of the Essence in Adult Acute Myeloid Leukemia

    Blood (e-Letter), 2010

    Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B

    Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese,, 2009

    Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient

    Alizadeh, A. A., Gentles, A. J., Plevritis, S. K., Levy, R., 2009

    Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes

    Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, , 2009

    Is Time of the Essence in Adult Acute Myeloid Leukemia

    Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., , 2009

    Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.

    Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, , 2009

    A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma

    Myklebust, J. H., Irish, J. M., Houot, R., Brody, J., Czerwinski, D. K, 2009

    Therapeutic Potential of Anti-CD137 Antibody in Lymphoma

    Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh,, 2009

    Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion

    BLOOD, 2009

    CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON

    Chao, M. P., Alizadeh, A., Tang, C. Z., Jan, M., Levy, R., Majeti, R.,, 2009

    A pluripotency signature predicts histological transformation

    Blood

    Evaluation and management of angioimmunoblastic T-cell lymphoma

    Clinical advances in hematology & oncology : H&O, 2008

    CD47 Is An Independent Prognostic Factor

    Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Weissman, I. L., 2008

    LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B

    Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Brion, 2008

    Double trouble in follicular lymphoma

    LEUKEMIA & LYMPHOMA, 2008

    Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan

    JOURNAL OF CLINICAL MICROBIOLOGY, 2007

    Cell-type specific gene expression profiles of leukocytes in human peripheral blood

    BMC GENOMICS, 2006

    Distinct IL-4-induced gene expression, proliferation

    BLOOD, 2005

    AID is expressed in germinal center B-cell-like

    LEUKEMIA, 2004

    Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53

    BLOOD, 2004

    Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

    NEW ENGLAND JOURNAL OF MEDICINE, 2004

    Gene expression signature of fibroblast serum response predicts human cancer progression

    PLoS biology, 2004

    Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock

    LANCET, 2004

    T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression

    PLOS BIOLOGY, 2003

    T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression.

    PLoS biology, 2003

    Rheumatoid arthritis is a heterogeneous disease

    ARTHRITIS AND RHEUMATISM, 2003

    Transformation of follicular lymphoma to diffuse large cell lymphoma is

    BLOOD, 2003

    Individuality and variation in gene expression patterns in human blood

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2003

    HGAL is a novel interleukin-4

    BLOOD, 2003

    Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling

    N Engl J Med, 2003

    Software tools for high-throughput analysis

    AMERICAN JOURNAL OF PATHOLOGY, 2002

    Genomic expression programs

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2002

    Transformation of follicular lymphoma to diffuse large-cell lymphoma

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2002

    The t(14;18) defines a unique subset of diffuse large B

    BLOOD, 2002

    In vivo regulation of human skeletal muscle gene expression by thyroid hormone

    GENOME RESEARCH, 2002

    Stereotyped and specific gene expression programs in human innate immune responses to bacteria

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2002

    Relation of gene expression phenotype to immunoglobulin mutation genotype

    JOURNAL OF EXPERIMENTAL MEDICINE, 2001

    Towards a novel classification of human malignancies based on gene expression patterns

    JOURNAL OF PATHOLOGY, 2001

    Genomic analysis of renal allograft dysfunction using cDNA microarrays

    Sarwal, M., Chang, S., Barry, C., Chen, X., Alizadeh, A., Salvatierra,, 2001

    Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 2000

    Exploring gene expression signatures of host responses to infection

    Boldrick, J. C., Belcher, C. E., Alizadeh, A. A., Liu, C. L., Diehn, M, 2000

    Examining the living genome in health and disease with DNA microarrays

    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000

    Genomic-scale gene expression profiling of normal and malignant immune cells

    CURRENT OPINION IN IMMUNOLOGY, 2000

    'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.

    Genome biology, 2000

    Gene expression in large B-cell lymphoma using cDNA microarray technology.

    Chan, W. C., Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H.,, 1999

    Genome-wide analysis of DNA copy-number changes using cDNA microarrays

    NATURE GENETICS, 1999

    Probing lymphocyte biology by genomic-scale gene expression analysis

    JOURNAL OF CLINICAL IMMUNOLOGY, 1998

    What is Dr. Alizadeh's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.

    Dr. Alizadeh's National Provider Identifier (NPI) number is 1295824423.

    What common questions do patients ask about Dr. Alizadeh?

    Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Alizadeh

    What is Dr. Arash Alizadeh's specialty?

    Dr. Alizadeh is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Alizadeh to book an appointment today.

    Is this Dr. Arash Alizadeh affiliated with a ranked Castle Connolly Top Hospital?

    Yes, Dr. Alizadeh is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals

    Where can I learn more about Medical Oncologist?

    Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.

    Is Arash Alizadeh accepting new patients in Stanford, CA?

    Yes, Dr. Arash Alizadeh is accepting new patients at this time.

    Does Dr. Arash Alizadeh offer online booking?

    Please contact Dr. Alizadeh's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.

    How can I make an appointment with Arash Alizadeh?

    Please contact Dr. Alizadeh's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.

    Which board certifications does Dr. Arash Alizadeh have?

    Dr. Arash Alizadeh is certified by the American Board of Internal Medicine.

    Other Medical Oncologist Near Stanford, CA

    NM

    Medical Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    JD

    Medical Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    AK

    Medical Oncologist

    acceptingPatients-iconAccepting patients
    Stanford, CA
    See All Specialists

    Doctors by Category

    Specialists